Pell Bio Med Technology Co Ltd
TWSE:6949
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pell Bio Med Technology Co Ltd
TWSE:6949
|
TW |
|
Cobra Resources PLC
LSE:COBR
|
UK |
|
Z
|
Zhejiang Hisun Biomaterials Co Ltd
SSE:688203
|
CN |
|
R
|
Randgold & Exploration Company Ltd
JSE:RNG
|
ZA |
Pell Bio Med Technology Co Ltd
Pell Bio-Med Technology Co., Ltd. operates as a biotechnology company. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-08. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The firm is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
Pell Bio-Med Technology Co., Ltd. operates as a biotechnology company. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-08. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The firm is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
